- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Nycomed’s Teslascan is approvable
Contrast agent developer Nycomed of Oslo, Norway, has received a second approvable letter from the Food and Drug Administration for its Teslascan (mangafodipir trisodium) liver imaging agent for MRI studies. Teslascan had received an approvable letter
Contrast agent developer Nycomed of Oslo, Norway, has received a second approvable letter from the Food and Drug Administration for its Teslascan (mangafodipir trisodium) liver imaging agent for MRI studies. Teslascan had received an approvable letter last September, but the FDA raised additional questions about the agent's application that the company has been working to resolve (SCAN 10/9/96). With the second approvable letter now in hand, Nycomed expects final approval shortly, according to a spokesperson for the company's U.S. subsidiary in Princeton, NJ.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
